tiprankstipranks
Trending News
More News >

Neurotech International Enhances US Presence with New Chief Medical Advisor

Story Highlights
Neurotech International Enhances US Presence with New Chief Medical Advisor

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Neurotech International ( (AU:NTI) ).

Neurotech International has appointed Dr. Bonni Goldstein as Chief Medical Advisor USA, enhancing its strategic capabilities in cannabinoid-based therapies for paediatric neurological disorders. Dr. Goldstein’s extensive experience and network are expected to bolster Neurotech’s regulatory strategy and clinical advancement in the US, particularly as the company progresses NTI164 towards commercialisation. Her appointment is seen as a strong validation of Neurotech’s innovative approach and the potential of NTI164 in treating neurological conditions, increasing the company’s visibility and impact in the US market.

More about Neurotech International

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing therapies for paediatric neurological disorders. The company is advancing a broad-spectrum oral cannabinoid drug therapy called NTI164, which has shown promising results in clinical trials for conditions such as Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome.

Average Trading Volume: 748,568

Technical Sentiment Signal: Sell

Current Market Cap: A$17.84M

See more insights into NTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1